ClinicalTrials.gg
RecruitingNCT06979336Updated Oct 27, 2026

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

A Phase 2 interventional study of RO7837195 and RO7837195 Matched Placebo in Ulcerative Colitis, sponsored by Genentech, Inc.. Recruiting at 111 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Oct 27, 2026Site recruiting status changed5 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Colitis, Ulcerative by Hoffmann-La Roche — 4 open to participants now, 6 under way, 4 of them phase 3. Colitis, Ulcerative · Hoffmann-La Roche.

Planned enrollment
11th of 24
224 · median 169
Started
2025
with 1 other
Phase 2
8 of 24
1 open now
Registered
21st of 24
by date

Among the 24 studies in Colitis, Ulcerative by Hoffmann-La Roche, this one is the 11th largest by planned enrollment, is one of 2 that started in 2025, is one of 8 in phase 2, and was the 21st registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

4 of the 24 studies in Colitis, Ulcerative by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Colitis, Ulcerative by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.

Read the detailed description

This study consists of up to 5-week screening period, a 12-week induction phase, a 40-week active treatment extension, and a safety follow-up period following the last dose of study treatment. The induction phase will be placebo-controlled and after its completion, all participants will receive treatment with active study drug, regardless of the treatment response.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ulcerative colitis (UC) established at least 3 months
  • Moderately to severely active UC assessed by mMS
  • Inadequate response, loss of response, or intolerance to conventional or advanced therapies for UC

Exclusion criteria

Exclusion Criteria:

  • Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for UC
  • Diagnosis of Crohn's disease or indeterminate colitis
  • Treatment with an advanced therapy targeted at tumor necrosis factor-like cytokine 1A (TL1a)
  • Inadequate response, loss of response, or intolerance to treatment of UC with an advanced therapy targeted at IL-12 and/or IL-23
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
224 participants (estimated)

Study arms

  • Experimental
    RO7837195 Dose Regimen 1

    Participants will receive RO7837195 per the pre-defined dosing regimen during the 12-week induction and 40-week active treatment extension phases.

    Drug: RO7837195

  • Experimental
    RO7837195 Dose Regimen 2

    Participants will receive RO7837195 per the pre-defined dosing regimen during the 12-week induction and 40-week active treatment extension phases.

    Drug: RO7837195

  • Experimental
    RO7837195 Dose Regimen 3

    Participants will receive RO7837195 per the pre-defined dosing regimen during the 12-week induction and 40-week active treatment extension phases.

    Drug: RO7837195

  • Experimental
    RO7837195 Dose Regimen 4

    Participants will receive RO7837195 per the pre-defined dosing regimen during the 12-week induction and 40-week active treatment extension phases.

    Drug: RO7837195

  • Experimental
    RO7837195 Matched Placebo/ RO7837195

    Participants will receive RO7837195 matched placebo and RO7837195 per the pre-defined dosing regimen during the 12-week induction and 40-week active treatment extension phases, respectively.

    Drug: RO7837195 · Drug: RO7837195 Matched Placebo

Interventions

  • DrugRO7837195

    RO7837195 will be administered as per the schedule specified in the protocol.

  • DrugRO7837195 Matched Placebo

    RO7837195 matched placebo will be administered as per the schedule specified in the protocol.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Remission at Week 12

    Clinical remission is defined as the Modified Mayo Score (mMS) of ≤ 2, including stool frequency subscore of ≤ 1, rectal bleeding subscore of 0, and endoscopy subscore of ≤ 1.

    Time frame: At Week 12

Secondary outcomes

  1. Percentage of Participants With Clinical Response at Week 12

    Clinical response is defined as decrease from baseline in the mMS by ≥2 and ≥ 30% reduction from baseline, with either a decrease of ≥1 in the rectal bleeding subscore or an absolute rectal bleeding subscore of ≤1.

    Time frame: At Week 12

  2. Percentage of Participants With Endoscopic Improvement at Week 12

    Endoscopic improvement is defined as a Mayo endoscopy subscore of ≤ 1.

    Time frame: At Week 12

  3. Percentage of Participants With Endoscopic Remission at Week 12

    Endoscopic remission is defined as a Mayo endoscopy subscore of 0.

    Time frame: At Week 12

  4. Number of Participants With Adverse Events (AEs)

    Time frame: Up to Weeks 65

  5. Serum Concentration of RO7837195

    Time frame: Up to Weeks 65

  6. Percentage of Participants With Anti-drug Antibodies to RO7837195

    Time frame: Up to Weeks 65

07

Study locations

106 of 111 sites recruiting

Showing the first 100 of 111 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Aug 2027, 22 months after the start.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's planned 22 months is below that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
May 18, 2025
StartActual
Sep 29, 2025
Primary completionEst.
Aug 25, 2027
CompletionEst.
Oct 31, 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added. 2 sites changed recruiting status (2 now withdrawn)
Show 2 sites
  • Nemocnice Slany · Slaný, CzechiaRecruiting→Withdrawn
  • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych Administracji · Warsaw, PolandRecruiting→Withdrawn
Show 5 added (2 Mexico, 1 United States, 1 Australia, 1 Italy)
  • Clinica de Investigacion en Reumatologia y Obesidad S.C. · Guadalajara, Mexico
  • Centro de Alta Especialidad en Reumatología e Investigación del Potosí, S.C. · San Luis Potosí City, Mexico
  • University of Rochester - PARENT · Rochester, United States
  • Royal Prince Alfred Hospital · Camperdown, Australia
  • Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
across 2 updates, Sep 28, 2026 – Oct 27, 2026
Show all 2 updates
  1. Oct 27, 2026
    3 sites added
    Show 3 added (1 United States, 1 Australia, 1 Italy)
    • University of Rochester - PARENT · Rochester, United States
    • Royal Prince Alfred Hospital · Camperdown, Australia
    • Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
    + 1 other change: verification date
  2. Sep 28, 2026
    2 sites added. 2 sites changed recruiting status (2 now withdrawn)
    Show 2 sites
    • Nemocnice Slany · Slaný, CzechiaRecruiting→Withdrawn
    • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych Administracji · Warsaw, PolandRecruiting→Withdrawn
    Show 2 added (2 Mexico)
    • Clinica de Investigacion en Reumatologia y Obesidad S.C. · Guadalajara, Mexico
    • Centro de Alta Especialidad en Reumatología e Investigación del Potosí, S.C. · San Luis Potosí City, Mexico
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06979336
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
May 18, 2025
Start date
Sep 29, 2025
Primary completion
Aug 25, 2027 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Reference Study ID Number: GA45977 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S.)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion